Extrawell Pharmaceutical Proposes 1-for-20 Share Consolidation

• Extrawell Pharmaceutical shareholders will vote on a 1-for-20 share consolidation and related capital restructuring at a special meeting on November 30, 2026.
• The restructuring would reduce issued shares' par value from HK$ 0.20 to HK$ 0.01, transferring approximately HK$ 27.55 million to contributed surplus.
• Authorized but unissued consolidated shares would be subdivided into 20 shares each, keeping authorized capital at HK$ 200 million.
• Subject to conditions, implementation is expected December 2, 2026; trading board lots would change from 10,000 existing shares to 1,000 new shares.
• Directors recommend voting in favor of the restructuring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Extrawell Pharmaceutical Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12401752), on November 05, 2026, and is solely responsible for the information contained therein.